CHÉOS is pleased to welcome Dr. Bohdan Nosyk and his Health Economic Research Unit (HERU) to our centre. Dr. Nosyk and his team join us from the BC Centre for Excellence in HIV/AIDS.
Currently, Dr. Nosyk is an associate professor in the Faculty of Health Sciences at Simon Fraser University (SFU) and the endowed St. Paul’s Hospital CANFAR Chair in HIV/AIDS Research. He holds a master’s degree in economics and a doctorate in public health, with a concentration in health economics, both from UBC.
Dr. Nosyk’s research has focused broadly on health economic evaluation and statistical and mathematical modeling in substance use and HIV/AIDS, informing complex policy decisions surrounding prevention and management in these disease areas.
Dr. Nosyk was a Health Economist at CHÉOS for several years before pursuing post-doctoral training at the University of California (Los Angeles) and serving as an adjunct scientist at the UCLA Integrated Substance Abuse Programs. While he was a research scientist at the BC Centre for Excellence in HIV/AIDS, he received the Michael Smith Foundation for Health Research Scholar Award in 2012. Dr. Nosyk has more than 150 peer-reviewed publications.
The HERU is a multidisciplinary team of health economists, statisticians, project coordinators, and students led by Dr. Nosyk. Laura Dale and Micah Piske are project coordinators. Megan Kurz, Charlie Zhou, Jeong Eun Min and Fahmida Homayra are HERU’s statisticians. Currently, they are joined by Roshni Desai and Lily Zhang, who are on secondment from FNHA to HERU. Benjamin Enns and Emanual Krebs are health economists. PhD student Trevor Thomson is also part of the team, along with casual research assistant Xiao Zang.
HERU’s program of research focuses primarily on statistical and cost-effectiveness analysis related to health service delivery in HIV/AIDS, substance use disorders and viral hepatitis. Recent publications include a comparison of youth and adults with opioid use disorder who are engaging in medication treatment, an examination of the effect of BC’s Pharmacare coverage expansion for opioid agonist treatment, and an analysis of the potential impacts of COVID-19 on the HIV epidemic by adding linked, opt-out HIV testing alongside SARS-CoV-2 testing.
Dr. Nosyk and his team are an exciting new addition to CHÉOS and will bolster the Centre’s position as a leader in health economics, statistics, and substance use research.
